Article

Diabetes and Frail Older Patients: Glycemic Control and Prescription Profile in Real Life

Anne-Sophie Mangé 1, Arnaud Pagès 1,2,3,*, Sandrine Sourdet 4, Philippe Cestac 1,2 and Cécile McCambridge 1

Abstract: (1) Background: The latest recommendations for diabetes management adapt the objectives of glycemic control to the frailty profile in older patients. The purpose of this study was to evaluate the proportion of older patients with diabetes whose treatment deviates from the recommendations. (2) Methods: This cross-sectional observational study was conducted in older adults with known diabetes who underwent an outpatient frailty assessment in 2016. Glycated hemoglobin (HbA1c) target is between 6% and 7% for nonfrail patients and between 7% and 8% for frail patients. Frailty was evaluated using the Fried criteria. Prescriptions of glucose-lowering drugs were analyzed based on explicit and implicit criteria. (3) Results: Of 110 people with diabetes with an average age of 81.7 years, 67.3% were frail. They had a mean HbA1c of 7.11%. Of these patients, 60.9% had at least one drug therapy problem in their diabetes management and 40.9% were potentially overtreated. The HbA1c distribution in relation to the targets varied depending on frailty status (p < 0.002), with overly strict control in frail patients (p < 0.001). (4) Conclusions: Glycemic control does not seem to be routinely adjusted to the health of frail patients. Several factors can lead to overtreatment of these patients.

Keywords: diabetes mellitus; frail elderly; glycated hemoglobin A; glycemic control; medical overuse

1. Introduction

Experts are increasingly taking frailty and drug tolerance into account in making recommendations to guide the treatment of older adults [1,2]. Frailty is defined as a clinical syndrome reflecting a decline in physiological reserves [3,4]. Currently, the most widespread approach for assessing frailty is the Fried Frailty Index, which uses five criteria: weight loss, exhaustion, slow walking speed, weakness, and low levels of physical activity [3]. Patients are considered “robust” if their score is 0, “prefrail” if their score is 1 or 2, and “frail” if it is 3, 4, or 5. Frailty is a transient state, potentially reversible if the geriatric patient receives appropriate treatment [1,5].

Older patients with diabetes are particularly at risk of iatrogenic events due to the accumulation of age-specific functional deficits and disease progression, comorbidities, and ensuing treatments. Therapeutic optimization aimed at reducing this risk includes decreasing the number of drugs, taking the drugs’ pharmacokinetic properties into account, and reassessing glycemic targets based on the patient’s health. Overly strict glycemic control can result in hypoglycemia, increasing the risk of dementia and falls [6,7]. It was with this in mind that the therapeutic targets were adjusted. Several national and international recommendations set different targets for HbA1c depending on the level of
frailty, allowing higher targets for frail patients [1,8–12]. Moreover, some glucose-lowering medications appear in lists of potentially inappropriate medications (PIMs) in older subjects because of their hypoglycemic properties, lack of proven efficacy, or lack of safety data [13].

The primary aim of this study was to assess the proportion of older people with diabetes whose treatment deviates from current recommendations. Additionally, we aimed to describe the nature of these deviations using the following items: HbA1c targets, PIMs, dosage adjustments to kidney function, contraindications, and hypoglycemia.

2. Materials and Methods

We performed a cross-sectional, observational, single-center study. We collected data from patients suffering from diabetes amongst those evaluated in 2016 at the Geriatric Frailty Clinic (GFC), an outpatient clinic of Toulouse University Hospital, France [14]. Data (sociodemographic data, medical history, and pharmaceutical treatments) were gathered for this study from the GFC software. Creatinine clearance was calculated using the Cockcroft formula. This study is reported in compliance with the STROBE guidelines [15].

These patients were referred to the GFC by their primary care physician to investigate whether they were frail or not, in order to provide them an individualized care plan [16]. For each patient, medication reconciliation was performed by the pharmacist and suggestions for therapeutic optimization were included in the individualized care plan. Furthermore, patients were asked for their approval before entering data for research purposes. The data were recorded in accordance with the French Data Protection Act and the General Data Protection Regulation (European Regulation No. 2016/679). The study was recorded in the register of the retrospective study of the Toulouse University Hospital (registration number: RnIPH 2021-75) and covered by MR-004 (CNIL number: 2206723 v 0). This study was approved by Toulouse University Hospital and confirmed to meet all the ethical requirements.

The glycemic balance was estimated by looking at a recent HbA1c assay (maximum 1 month old) or one performed during the geriatric assessment and compared with recommended targets. We defined HbA1c targets according to various guidelines [1,9,10] commonly used in France at the time of the study. These guidelines do not provide a lower limit, but morbidity/mortality studies such as the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study and the Veterans Affairs Diabetes Trial (VADT) describe the risk of tight glycemic control (HbA1c < 6%) [17,18]. Therefore, we defined the following targets: between 6 and 7% for nonfrail patients and between 7 and 8% for frail patients. The missing data concerned only the HbA1c assay. These patients were excluded from the analysis for the glycemic balance. Frailty was evaluated using the Fried criteria [3]. Robust or prefrail patients with a Fried score of 0 to 2 were classified as “nonfrail”, while those with a score of ≥3 were considered “frail”.

The potential inappropriateness of glucose-lowering drug prescriptions was analyzed based on explicit criteria (European list of PIMs [13]) and implicit criteria (kidney function, HbA1c, history, and frailty level). As there are many explicit criteria tools available, we chose the EU(7)-PIM list instead of the Beers criteria because this list is more suitable to prescribing practices in Europe, and our study was conducted in France [19]. Prescriptions were classified as “potentially inappropriate” when there was at least one discrepancy with the reference standards. We categorized the drug therapy problems based on the criteria determined by the French Society of Clinical Pharmacy (SFPC): deviation from the reference standards (i.e., a PIM according to the European list), a contraindication, an overdose (dosage higher than the maximum recommended dose or HbA1c lower than identified target and dosage that could be decreased), an undertdose (HbA1c higher than recommended target for which the dosage could be increased), a drug that is not indicated (HbA1c lower than identified target and treatment at the recommended minimum dosage or potentially harmful), an insufficiently treated indication (HbA1c higher than target requiring additional treatment), and occurrence of an adverse event [20]. We also considered the patient’s clinical geriatric assessment. We gathered proposals for thera-
peutic optimization of diabetes management by the pharmacist in consultation with the geriatrician.

Qualitative variables were described as numbers and percentages. The quantitative variables were calculated as means and standard deviations in the case of normal distribution, and as an interquartile interval (25th and 75th percentile of the distribution) if otherwise. The normality of the distribution was assessed by a graphical method and optionally by a Kolmogorov–Smirnov test.

To test the association between frailty and other qualitative variables of interest, we used the $\chi^2$ test if the validity conditions were met; otherwise, we used Fisher’s exact test. To compare the means between frail and nonfrail patients (i.e., robust or prefrail patients) (bilateral test), we used the Student’s $t$ test if distribution was normal or the Wilcoxon signed-rank test if distribution was not normal. A difference was considered statistically significant for a $p$ value of less than or equal to 0.05. The statistical analyses were performed using SAS 9.3 software (SAS Institute, Cary, NC, USA).

3. Results
3.1. Characteristics of Study Population

Of the 929 outpatients evaluated at the Toulouse GFC in 2016, 11.8% ($n = 110$) were known as suffering from diabetes. The general characteristics and treatment strategies for this population are described in Table 1.

Table 1. General population characteristics ($n = 110$).

| Patient Characteristics | Statistics |
|-------------------------|------------|
| Age (mean, standard deviation) | 81.7 ± 6 |
| Female ($n$, %) | 68 (61.8%) |
| Weight (mean, standard deviation) | 73.49 ± 14.6 |
| Kidney function ($n = 108$) | |
| Serum creatinine ($\mu$mol/L) (mean, standard deviation) | 101.1 ± 78.6 |
| Creatinine clearance (mL/min) (mean, standard deviation) | 55.8 ± 20.6 |
| No CKD ($n$, %) | 7 (6.5%) |
| Mild CKD: creatinine clearance between 60 and 90 mL/min ($n$, %) | 35 (32.4%) |
| Moderate CKD: creatinine clearance between 30 and 60 mL/min ($n$, %) | 55 (50.9%) |
| Severe CKD: creatinine clearance < 30 mL/min ($n$, %) | 11 (10.2%) |
| Frailty ($n = 109$) | |
| Fried score (median, (Q25, Q75)) | 3 [2; 4] |
| Fried frailty criteria | |
| Weight loss ($n$, %) | 22 (20.0%) |
| Feelings of exhaustion ($n$, %) | 57 (52.3%) |
| Muscle weakness ($n$, %) | 90 (82.6%) |
| Reduced walking speed ($n$, %) | 64 (58.7%) |
| Sedentary lifestyle ($n$, %) | 87 (79.1%) |
| Falls ($n = 107$) | |
| Yes ($n$, %) | 36 (33.6%) |
Table 1. Cont.

| Treatment                                                                 | Statistics            |
|---------------------------------------------------------------------------|-----------------------|
| Number of medications prescribed $^d$ (mean, standard deviation)          | $8.2 \pm 3.3$         |
| Number of glucose-lowering medication (mean, standard deviation)          | $1.4 \pm 1.0$         |
| Therapeutic strategy (n, %)                                               | N (%)                 |
| Lifestyle changes only                                                    | 20 (18.2%)            |
| Oral glucose-lowering drug only                                           | 51 (46.4%)            |
| 1 OGLD                                                                    | 32 (29.1%)            |
| 2 OGLDs                                                                  | 17 (15.5%)            |
| $\geq$ 3 OGLDs                                                           | 2 (1.8%)              |
| Oral glucose-lowering drug + Insulin                                      | 17 (15.5%)            |
| 1 OGLD + Insulin                                                         | 9 (8.2%)              |
| $\geq$ 2 OGLDs + Insulin                                                 | 8 (7.3%)              |
| Insulin only                                                             | 22 (20.0%)            |

Legend: CKD: chronic kidney disease; OGLD: Oral glucose-lowering drugs. $^a$ $n = 2$ for kidney function; $^b$ $n = 1$ for frailty score, feeling of exhaustion, reduced walking speed, muscle weakness; $^c$ $n = 3$ for falls; $^d$ $n = 2$ for number of prescribed medications.

According to the Fried criteria, 67.3% of the patients were frail. Polypharmacy (5 or more medications) affected 79.6% ($n = 86$) of patients. All of the patients in our study were taking at least one medication, with 2 to 20 drugs per patient (not including self-medication). Table A1 in Appendix A details the various glucose-lowering medication prescribed.

3.2. Analysis of Glucose-Lowering Drug Prescriptions’ Appropriateness

The drug therapy problems (DTPs) found in our analysis of diabetes management are described in Table 2. We calculated the subtotal corresponding to patients with at least 1 DTP without taking into account Acarbose and Liraglutide since these two criteria may be controversial.

Out of 110 patients, 67 (60.9%) had more than one DTP. The mean number of DTP for these 67 patients was 1.45. Of these patients, 40.9% ($n = 45$) were potentially overtreated, with at least one drug that was either not indicated and/or overdosed; 16.4% ($n = 18$) were insufficiently treated. Among patients with at least one DTP, one or more therapeutic optimization recommendations were made for 39 patients.

With regard to dose adjustment to renal function, we had the estimate of the Glomerular Filtration Rate (GFR) for each patient, as determined from serum creatinine using the Cockroft and Gault formula. The proportion of patients with a dosage that was not appropriate for their GFR was verified. Table A2 details the distribution of prescriptions at inappropriate dosages for impaired kidney function.

3.3. Analysis of Glycemic Balance

One hundred patients had a recent HbA1c assay (missing data: $n = 10$). The mean HbA1c calculated was 7.11% ($\pm 1.11$). Figure 1 shows the compliance with HbA1c targets based on frailty.
Table 2. Drug therapy problems identified in diabetes management ($n = 110$).

| Types of Problems | $n = 110$ |
|-------------------|-----------|
| **According to EU(7) PIM List** | |
| Long-acting sulphonylureas (glibenclamide, glimepiride) | 4 (3.6%) |
| Acarbose | 3 (2.7%) |
| Sliding-scale insulin | 5 (4.6%) |
| **Contraindication** | 2 (1.8%) |
| **Overdose** | |
| No adjustment to renal function | 20 (18.2%) |
| Medication used at excessively high dose | 10 (9.1%) |
| **Underdose** | 14 (12.7%) |
| Overly tight glycemic control relative to glycemic targets | 22 (20.0%) |
| Pharmacological redundancy | 1 (0.9%) |
| Liraglutide in a patient over 75 years | 1 (0.9%) |
| **Indication not treated or insufficiently treated** | 4 (3.6%) |
| **Hypoglycemia** | 10 (9.1%) |
| **Subtotal**: patients with at least 1 DTP without taking into account Acarbose and Liraglutide | 66 (60.0%) |
| **Total (patients with at least 1 DTP)** | 67 (60.9%) |

Legend: EU(7) PIM list: European list of potentially inappropriate medications; DTP: drug therapy problems (one patient can have several drug therapy problems). Dosage adjustments for patients with kidney failure (according to the Summaries of Product Characteristics available in 2016): Metformin: 1500 mg maximum per day if creatinine clearance is between 30 and 60 mL/min; contraindicated if creatinine clearance is <30 mL/min). Sitagliptin: 50 mg maximum per day if creatinine clearance is between 30 and 50 mL/min; 25 mg maximum per day if creatinine clearance is <30 mL/min. Acarbose: contraindicated if creatinine clearance is <25 mL/min.

Figure 1. Patient distribution according to HbA1c targets ($n = 100$). HbA1c = glycated hemoglobin. Compliance with HbA1c targets varied significantly depending on whether the patients were frail or not; * $p < 0.002$. These data show that frail patients are more likely to be below the glycemic targets compared with nonfrail patients ($p < 0.001$). The HbA1c distribution based on the level of frailty is detailed in Figure A1. Glycated hemoglobin levels and glucose-lowering treatments based on frailty level are described in Table A3.
3.4. Hypoglycemic Episodes

Hypoglycemic episodes were suspected or confirmed in 9.1% of the patients ($n = 10$), with no significant difference between frail and nonfrail patients ($p = 0.99$). Of these patients, 7 were treated with insulin therapy, including one in combination with repaglinide; and 2 were treated with long-acting sulfonylureas. One patient developed hypoglycemia on monotherapy with repaglinide. Alongside these hypoglycemic episodes, we analyzed falls. Of the 23 patients with falls who were being treated “pharmacologically” and for whom a recent HbA1c was available, 47.8% ($n = 11$) had an HbA1c below the target. Of the patients with falls, one-third ($n = 12$) were taking a hypoglycemic agent (insulin, sulfonylurea, or repaglinide).

4. Discussion

We noticed that diabetes management deviated from the recommendations for 60.9% of our study’s patients, and that 40.9% were potentially overtreated. We found that the glycemic objectives are not always suited to the health of the frailest patients, and the therapeutic streamlining allowed by the recommendations is not always applied. The overtreatment in frail elderly is a well-described topic in publications, including people with diabetes [21–23]. Our work describes various items of this overtreatment: the HbA1c targets adjusted for frailty, dosage adjustments to kidney function, and the concept of a PIM, which explains the high rate of DTP.

Regarding glucose lowering medications with a poor risk/benefit ratio, the EU(7)-PIM list mentions: fast insulin catch-up protocols, long-acting sulfonylureas, and acarbose. Because of their prolonged hypoglycemic effects, long-acting sulfonylureas are not recommended for the elderly, according to the international PIM list [13,24,25]. We found their prescription rate to be low (3.6%). Although the European list mentions glibenclamide and glimepiride as PIMs in older subjects, only the STOPP/START.v2 list additionally mentions gliclazide LM as inappropriate [13,25]. On the other hand, the European list proposes this one as a safer alternative. The Schernthaner study compared the safety of gliclazide LM with that of glimepiride. It found gliclazide to be significantly less hypoglycemic (3.7% vs. 8.9%; $p < 0.003$), with at least similar efficacy [26]. Given the literature, the place of sulfonylureas in the recommendations, and their efficacy, Gliclazide can be an alternative when other agents are not available for monitoring hypoglycemic risk. Concerning DPP4 inhibitors, the European list criticizes them for the lack of clinical safety data in older subjects. However, the latest French and European recommendations position them as second-line treatments [1,8–10]. Moreover, studies in older subjects are thought to favor their safe use, especially when individualized HbA1c targets are set [27,28]. Thus, we have deliberately not considered them as drug therapy problems.

Changes in the pharmacokinetic properties of the drugs in older subjects have to be considered in preventing drug-induced reactions. The OREDIA study was concerned with the treatment of older diabetes patients with kidney failure [22]. Of our patients with kidney failure, one-third had at least one drug for which the dosage should have been adjusted or replaced with an alternative treatment. As in OREDIA, we were able to conclude that impaired kidney function is not sufficiently taken into account in prescribing oral glucose-lowering drugs. Metformin was the drug most often found in these failures to adjust.

Although national recommendations did not recommend a lower limit for HbA1c targets, more recent national publications with European and international recommendations propose lower limits between 7% and 7.6%, particularly in frail patients [8–10]. Moreover, the targets proposed in the recent Sinclair’s international recommendations match with those used in our work [9]. This confirms the relevance of our targets. Several studies analyzed the relationship between mortality and glycemic control in older patients and described it as a U-shaped curve. The best-tolerated HbA1c levels are between 6% and 9%, with the lowest risk being at 7.5% [29–31]. Therefore, we defined the lower limit for HbA1c as 6% and 7% for nonfrail and frail patients, respectively. Thus, we found that a
significantly larger percentage of frail patients had HbA1c levels below the target for their frailty status. This reinforces our previous observation regarding failure to adjust glycemic control for aging.

The GERODIAB and GUIDANCE studies concluded that glycemic control was too strict in older patients [23,32]. Subjects were enrolled in these studies before the new recommendations were published. Our study brings up a problem of compliance with the latest recommendations. This low adherence has also been discussed in other recent studies [33]. In order to improve it and reduce the overtreatment, the benefit of a multidisciplinary medication review combined with clinical pharmacist expertise is well described in both people with diabetes and elderly patients [34–36].

Hypoglycemic episodes increase the risk of falls, myocardial ischemia, impaired cognitive function, and mortality, and thus have to be prevented in elderly [37]. We identified 9.1% of patients as having had at least one hypoglycemic episode in the months preceding this study. The hypoglycemic histories we collected were patient-reported, so it is highly likely that the incidence of these events was underestimated. In older subjects, symptoms often go unnoticed, with vague and atypical symptoms, which complicates diagnosis after the fact. It is important to investigate any episode suggestive of hypoglycemia (dizziness, falls, etc.). Of the patients in our study who had fallen, almost one-third had glycemic control that was too strict as compared to the objectives. One-third were treated with at least one hypoglycemic agent. Although an older patient with diabetes may present with several reasons for a fall (peripheral neuropathy, muscle weakness, poor vision, etc.), the possibility of hypoglycemia should not be overlooked. The question of self-monitoring plasma glucose or stepping down treatment can be raised in these patients.

The main limitation of this study is the cross-sectional and monocentric design, which limits the generalizability of the results. We can also mention the limits for evaluating glycemic control in a single HbA1c assay, whose reliability may be influenced by certain factors impacting the turnover of red blood cells.

One of the strong points of our study is the use of the Fried score to identify frail patients. This allowed us to provide a documented estimate of the glycemic targets adjusted to the patient’s health. Moreover, the prescription analysis was done by pharmacists specialized in geriatrics and optimization recommendations were made in consultation with a multidisciplinary team. Finally, the use of implicit and explicit criteria to evaluate drug therapy problems increases the thoroughness of the analysis and the relevance of the recommendations.

5. Conclusions

This study provides an account of the prescription profile and glycemic control in Geriatric Frailty Clinic patients from Toulouse University Hospital in France. Several elements can lead to overtreatment in the frailest patients. The difficulty of managing older patients with diabetes lies in the search for a balance between abandoning treatment out of resignation and a fear of drug-induced reactions, and excessive intervention unsuited to the patients’ health status. The lack of a lower target in the national recommendations does not encourage deprescribing, especially in patients deemed to be stable. This raises the problem of reevaluating chronic diseases in stable but frail patients.

Author Contributions: Conceptualization, A.-S.M., A.P., C.M., S.S. and P.C.; methodology, A.-S.M., A.P., C.M., S.S. and P.C.; software, A.P.; validation, C.M., S.S. and P.C.; formal analysis, A.P.; investigation, A.-S.M. and C.M.; resources, S.S.; data curation, A.-S.M. and C.M.; writing—original draft preparation, A.-S.M.; writing—review and editing, A.P., C.M., S.S. and P.C.; visualization, A.-S.M.; supervision, C.M.; project administration, C.M.; funding acquisition, C.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: According to French ethical and regulatory laws, retrospective/prospective studies based on the exploitation of usual care data should not be submitted to an
ethics committee. Instead, they must be declared following the reference methodology outlined by the French National Commission for Informatics and Liberties (CNIL). The collection and processing of personal and medical data was implemented to analyze the results of the research. Toulouse University Hospital signed a commitment of compliance to the CNIL’s reference methodology MR-004. Upon evaluation and validation by the data protection officer, according to the General Data Protection Regulation, this study fulfilled all the necessary criteria. It was recorded in the register of the retrospective study of the Toulouse University Hospital (registration number: RnIPH 2021-75) and covered by MR-004 (CNIL number: 2206723 v 0). This study was approved by Toulouse University Hospital on the 15 January 2021 and confirmed to meet all the ethical requirements outlined in the above report.

Data Availability Statement: Research data are not shared.

Acknowledgments: The authors thank Anne Ghisolfi and Bruno Vellas for their expertise and their support in this project. We thank the Geriatric Frailty Clinic team for their participation in this work, as well as Joanne Archambault and Joan Wallace for the translation of this article.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A

Table A1. Prescriptions of glucose-lowering drugs (90 patients).

| Label                                      | Number of Prescribed Medications (n = 151) | Average Daily Dosage |
|--------------------------------------------|--------------------------------------------|----------------------|
| **Insulins and analogs**                   |                                            | IU                   |
| Rapid-acting injectable insulins and analogs| 14 (9.3%)                                  |                      |
| Insulins and analogs with intermediate or long-acting action and rapid onset of action by injection | 1 (0.7%)                                  |                      |
| **Long-acting injectable insulins and analogs** | 38 (25.2%)                                 |                      |
| Insulin glargine                           | 28                                         | 20.0                 |
| Insulin detemir                            | 10                                         | 21.5                 |
| **Glucose-lowering drugs other than insulins** |                                            | mg                   |
| Biguanide                                  | 50 (33.1%)                                 | 1739.0               |
| Sulfonyleurea drugs                        | 13 (8.6%)                                  |                      |
| Glibenclamide                              | 1                                          | 7.5                  |
| Gliclazide                                 | 9                                          | 85.6                 |
| Glimepiride                                | 3                                          | 1.7                  |
| Alpha glucosidase inhibitors               | 3 (2.0%)                                   | 150.0                |
| Dipeptidyl Peptidase 4 (DPP-4) inhibitors  | 19 (12.6%)                                 |                      |
| Sitagliptin                                | 15                                         | 96.4                 |
| Vildagliptin                               | 4                                          | 75.0                 |
| Glucagon-Like-Peptide-1 (GLP-1) Analogs    | 2 (1.3%)                                   |                      |
| Liraglutide                                | 2                                          | 1.5                  |
| Repaglinide                                | 11                                         | 2.6                  |
Table A2. Distribution of potentially inappropriate medications (PIMs) related to kidney failure depending on frailty.

|                          | Nonfrail Patients (FRIED Score: 0 to 2) | Frail Patients (FRIED Score: 3 to 5) | Total       |
|--------------------------|----------------------------------------|-------------------------------------|-------------|
| Number of patients       |                                        |                                     |             |
| for whom all treatments  | 8 (36.4%)                              | 25 (56.8%)                          | 33 (50%)    |
| are adjusted to kidney   |                                        |                                     |             |
| function                 |                                        |                                     |             |
| Number of patients       | 8 a (36.4%)                            | 13 b (29.5%)                        | 21 (31.8%)  |
| with at least 1 PIMs     |                                        |                                     |             |
| related to renal failure |                                        |                                     |             |
| Metformin                | 6 (27.3%)                              | 12 (27.3%)                          | 18 (27.3%)  |
| Sitagliptin              | 3 (13.6%)                              | 5 (11.4%)                           | 8 (12.1%)   |
| Acarbose                 | 1 (4.5%)                               | 0 (0%)                              | 1 (1.5%)    |

a 2 Nonfrail patients with 2 PIMs (overuse of metformin and sitagliptin); b 4 frail patients with 2 PIMs (overuse of metformin and sitagliptin). Dosage adjustments for patients with kidney failure (according to the Summaries of Product Characteristics available in 2016): Metformin: 1500 mg maximum per day if creatinine clearance is between 30 and 60 mL/ min; contraindicated if creatinine clearance is <30 mL/ min. Sitagliptin: 50 mg maximum per day if creatinine clearance is between 30 and 50 mL/min; 25 mg maximum per day if creatinine clearance is <30 mL/ min. Acarbose: contraindicated if creatinine clearance is < 25 mL/min.

Table A3. Description of glycemic control and prescription profile of patients according to their frailty phenotype.

|                          | Nonfrail Patients (FRIED Score: 0 to 2) | Frail Patients (FRIED Score: 3 to 5) | p Value |
|--------------------------|----------------------------------------|-------------------------------------|---------|
| HbA1c level              |                                        |                                     |         |
| ≤7%                      | 22 (64.7%)                             | 34 (51.5%)                          | 0.35 *  |
| between 7% and 8%        | 6 (17.6%)                              | 20 (30.3%)                          |         |
| >8%                      | 6 (17.6%)                              | 12 (18.2%)                          |         |
| Drugs                    |                                        |                                     |         |
| Number of glucose-lowering drugs | 1.3                                     | 1.4                                 | 0.79 #  |
|                           | ± 1.0                                  | ± 1.0                               |         |
| No drugs                 | 7 (19.4%)                              | 13 (17.6%)                          |         |
| OGLDs only               | 19 (52.8%)                             | 32 (43.2%)                          | 0.66 *  |
| Insulin                  | 5 (13.9%)                              | 17 (23.0%)                          |         |
| OGLDs + Insulin          | 5 (13.9%)                              | 12 (16.2%)                          |         |

HbA1c = glycated hemoglobin; OGLDs = oral glucose-lowering drugs, * chi-square test, # Wilcoxon test.
Figure A1. Distribution according to glycemic control and frailty ($n = 100$); HbA1c = glycated hemoglobin. Additional information—comparison of 3 groups: less than 7%, between 7 and 8%, more than 8% (chi-square test); $p$-value = 0.35.

References

1. Haute Autorité de Santé—Stratégie Médicamenteuse du Contrôle Glycémique du Diabète de Type 2. Available online: https://www.has-sante.fr/portail/jcms/c_1022476/fr/strategie-medicamenteuse-du-controle-glycemique-du-diabete-de-type-2 (accessed on 8 July 2017).
2. Blacher, J.; Halimi, J.-M.; Hanon, O.; Mourad, J.-J.; Pathak, A.; Schnebert, B.; Girerd, X. Prise en charge de l'hypertension artérielle de l'adulte. Recommandations 2013 de la Société française d’hypertension artérielle. *Presse Méd.* 2013, 42, 819–825. [CrossRef] [PubMed]
3. Fried, L.P.; Tangen, C.M.; Walston, J.; Newman, A.B.; Hirsch, C.; Gottdiener, J.; Seeman, T.; Tracy, R.; Kop, W.J.; Burke, G.; et al. Frailty in Older Adults Evidence for a Phenotype. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* 2001, 56, M146–M157. [CrossRef] [PubMed]
4. Clegg, A.; Young, J.; Iliffe, S.; Rikkert, M.O.; Rockwood, K. Frailty in Elderly People. *Lancet* 2013, 381, 752–762. [CrossRef]
5. Lang, P.-O.; Michel, J.-P.; Zekry, D. Frailty Syndrome: A Transitional State in a Dynamic Process. *Gerontology* 2009, 55, 539–549. [CrossRef]
6. Lee, A.K.; Rawlings, A.M.; Lee, C.J.; Gross, A.L.; Huang, E.S.; Sharrett, A.R.; Coresh, J.; Selvin, E. Severe Hypoglycaemia, Mild Cognitive Impairment, Dementia and Brain Volumes in Older Adults with Type 2 Diabetes: The Atherosclerosis Risk in Communities (ARIC) Cohort Study. *Diabetologia* 2018, 61, 1956–1965. [CrossRef] [PubMed]
7. Malabu, U.; Vangaveti, V.; Kennedy, L. Disease Burden Evaluation of Fall-Related Events in the Elderly Due to Hypoglycemia and Other Diabetic Complications: A Clinical Review. *Clin. Epidemiol.* 2014, 6, 287–294. [CrossRef]
8. Darmon, P.; Bauduceau, B.; Bordier, L.; Charbonnel, B.; Cosson, E.; Detournay, B.; Fontaine, P.; Grimaldi, A.; Gourdy, P.; Guerci, B.; et al. Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l’hyperglycémie du patient diabétique de type 2—2019. 121. * Méd. Mal. M étabol.* 2019, 13, 22. [CrossRef]
9. Sinclair, A.J.; Abdelhafiz, A.; Dunning, T.; Izquierdo, M.; Rodriguez Manas, L.; Bourdel-Marchasson, I.; Morley, J.E.; Munshi, M.; Woo, J.; Vellas, B. An International Position Statement on the Management of Frailty in Diabetes Mellitus: Summary of Recommendations 2017. *J. Frailty Aging* 2018, 7, 10–20. [CrossRef]
10. Sinclair, A.J.; Paolizzo, G.; Castro, M.; Bourdel-Marchasson, I.; Gadsby, R.; Manãs, L.R. European Diabetes Working Party for Older People 2011 Clinical Guidelines for Type 2 Diabetes Mellitus. Executive Summary. *Diabetes Metab.* 2011, 37, S27–S38. [CrossRef]
11. American Diabetes Association. 7. Diabetes Technology: Standards of Medical Care in Diabetes—2019. *Diabetes Care* 2021, 44, S85–S99. [CrossRef]
12. Meneilly, G.S.; Knip, A.; Miller, D.B.; Sherifali, D.; Tessier, D.; Zahedi, A. Diabetes in Older People. Can. J. Diabetes 2018, 42, S283–S295. [CrossRef]  
13. Renom-Guiteras, A.; Meyer, G.; Thürmann, P.A. The EU(7)-PIM List: A List of Potentially Inappropriate Medications for Older People Consented by Experts from Seven European Countries. Eur. J. Clin. Pharmacol. 2015, 71, 861–875. [CrossRef] [PubMed]  
14. The Geriatric Frailty Clinic (G.F.C) for Assessment of Frailty and Prevalence of Disability Team; Tavassoli, N.; Guyonnet, S.; Abellan Van Kan, G.; Sourdet, S.; Krams, T.; Soto, M.-E.; Subra, J.; Chicoula, B.; Ghisolfi, A.; et al. Description of 1108 Older Patients Referred by Their Physician to the “Geriatric Frailty Clinic (G.F.C) for Assessment of Frailty and Prevalence of Disability” at the Gerontopôle. J. Nutr. Health Aging 2014, 18, 457–464. [CrossRef] [PubMed]  
15. von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P. STROBE Initiative Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. BMJ 2007, 335, 806–808. [CrossRef]  
16. Demougeot, L.; van Kan, G.A.; Vellas, B.; de Souto Barreto, P. Frailty Detection with the Gérontopôle Frailty Screening Tool (GFST). J. Frailty Aging 2013, 2, 150–152. [CrossRef]  
17. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein, H.C.; Müller, M.E.; Byington, R.P.; Goff, D.C.; Bigger, J.T.; Buse, J.B.; Cushman, W.C.; Genuth, S.; Ismail-Beigi, F.; et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N. Engl. J. Med. 2008, 358, 2545–2559. [CrossRef]  
18. Duckworth, W.; Abraira, C.; Moritz, T.; Reda, D.; Emanuele, N.; Zieve, F.J.; Marks, J.; Davis, S.N.; Hayward, R.; et al. Glycemic Control and Vascular Complications in Veterans with Type 2 Diabetes. N. Engl. J. Med. 2009, 360, 129–139. [CrossRef]  
19. Motter, F.R.; Fritzen, J.S.; Hilmer, S.N.; Paniz, V.M.V.; Potentially Inappropriate Medication in the Elderly: A Systematic Review of Validated Explicit Criteria. Eur. J. Clin. Pharmacol. 2018, 74, 679–700. [CrossRef] [PubMed]  
20. Allenet, B.; Bedouch, P.; Rose, F.-X.; Escofier, L.; Roubille, R.; Charpiat, B.; Juste, M.; Conort, O. Validation of an Instrument for the Documentation of Clinical Pharmacists’ Interventions. Pharm. World Sci. 2006, 28, 181–188. [CrossRef]  
21. Lipska, K.J.; Ross, J.S.; Miao, Y.; Shah, N.D.; Lee, S.J.; Steinman, M.A. Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control. JAMA Intern. Med. 2015, 175, 356. [CrossRef] [PubMed]  
22. Dejager, S.; Penfornis, A.; Fiquet, B.; Blickle, J.F. Potential Glycemic Overtreatment in Patients >75 years with Type 2 Diabetes Mellitus and Renal Disease: Experience from the Observational OREDIA Study. Diabetes Metab. Syndr. Obes. Targets Ther. 2015, 8, 303. [CrossRef] [PubMed]  
23. Müller, N.; Khunti, K.; Kuss, O.; Lindblad, U.; Nolan, J.J.; Rutten, G.E.; Trento, M.; Porta, M.; Roth, J.; Charpentier, G.; et al. Is There Evidence of Potential Overtreatment of Glycaemia in Elderly People with Type 2 Diabetes? Data from the GUIDANCE Study. Acta Diabetol. 2017, 54, 209–214. [CrossRef] [PubMed]  
24. 2019 American Geriatrics Society Beers Criteria® Update Expert Panel; Fick, D.M.; Semla, T.P.; Steinman, M.; Beizer, J.; Brandt, N.; Dombrowski, R.; DuBeau, C.E.; Pezullo, L.; Epplin, J.J. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 2019, 67, 674–694. [CrossRef]  
25. O’Mahony, D.; O’Sullivan, D.; Byrne, S.; O’Connor, M.N.; Ryan, C.; Gallagher, P. STOPP/START Criteria for Potentially Inappropriate Prescribing in Older People: Version 2. Age Ageing 2015, 44, 213–218. [CrossRef] [PubMed]  
26. Scherthaner, G.; Grimaldi, A.; Di Mario, U.; Drzewoski, J.; Kempler, P.; Kwapil, M.; Novials, A.; Rottiers, R.; Rutten, G.; Shaw, K.M. GUIDE Study: Double-Blind Comparison of Once-Daily Glitazide MR and Glimepiride in Type 2 Diabetic Patients. Eur. J. Clin. Investig. 2004, 34, 535–542. [CrossRef]  
27. Strain, W.D.; Lukashevich, V.; Kothy, W.; Hoellinger, M.; Paládinius, P.M. Individualised Treatment Targets for Elderly Patients with Type 2 Diabetes Using Vildagliptin Add-on or Lone Therapy (INTERVAL): A 24 Week, Randomised, Double-Blind, Placebo-Controlled Study. Lancet 2013, 382, 409–416. [CrossRef]  
28. Bethel, M.A.; Engel, S.S.; Green, J.B.; Huang, Z.; Josse, R.G.; Kaufman, K.D.; Standl, E.; Suryawanshi, S.; Van de Werf, F.; McGuire, D.K.; et al. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care 2017, 40, 494–501. [CrossRef] [PubMed]  
29. Currie, C.J.; Peters, J.R.; Tynan, A.; Evans, M.; Heine, R.J.; Bracco, O.L.; Zagar, T.; Poole, C.D. Survival as a Function of HbA1c in Type 2 Diabetes: The IMPLICA2 Study. Diabetes Care 2015, 38, 1920–1927. [CrossRef] [PubMed]  
30. Shurraw, S.; Hemmelgarn, B.; Lin, M.; Majumdar, S.R.; Klarenbach, S.; Manns, B.; Bello, A.; James, M.; Turin, T.C.; Tonelli, M.; et al. Association between Glycemic Control and Adverse Outcomes in People with Diabetes Mellitus and Chronic Kidney Disease: A Population-Based Cohort Study. Arch. Intern. Med. 2011, 171, 1920–1927. [CrossRef]  
31. Huang, E.S.; Liu, J.Y.; Moffet, H.H.; John, P.M.; Karter, A.J. Glycemic Control, Complications, and Death in Older Diabetic Patients: The Diabetes and Aging Study. Diabetes Care 2011, 34, 1329–1336. [CrossRef] [PubMed]  
32. Doucet, J.A.; Baudouc, B.; Le Floch, J.-P.; Verny, C.; The SFD/SFGG Intergroup. Medical Treatments of Elderly, French Patients with Type 2 Diabetes: Results at Inclusion in the GERODIAB Cohort. Fundam. Clin. Pharmacol. 2016, 30, 76–81. [CrossRef] [PubMed]  
33. Franch-Nadal, J.; García-Gollarte, F.; Pérez Del Molino, A.; Orera-Peña, M.I.; de Miguel, M.R.; Melogno-Klinkas, M.; de Paz, H.D.; Aceituno, S.; Rodriguez-Fortúnez, P. Physicians’ and Pharmacists’ Clinical Considerations for Elderly Patients with Type 2 Diabetes Mellitus: The IMPILCA2 Study. Clin. Drug Investig. 2019, 39, 73–84. [CrossRef]
34. Siaw, M.Y.L.; Ko, Y.; Malone, D.C.; Tsou, K.Y.K.; Lew, Y.-J.; Foo, D.; Tan, E.; Chan, S.C.; Chia, A.; Sinaram, S.S.; et al. Impact of Pharmacist-Involved Collaborative Care on the Clinical, Humanistic and Cost Outcomes of High-Risk Patients with Type 2 Diabetes (IMPACT): A Randomized Controlled Trial. *J. Clin. Pharm. Ther.* 2017, 42, 475–482. [CrossRef] [PubMed]

35. Pousinho, S.; Morgado, M.; Falcão, A.; Alves, G. Pharmacist Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. *J. Manag. Care Spec. Pharm.* 2016, 22, 493–515. [CrossRef] [PubMed]

36. Van der Linden, L.; Decoutere, L.; Walgraeve, K.; Milisen, K.; Flamant, J.; Spriet, I.; Tournoy, J. Combined Use of the Rationalization of Home Medication by an Adjusted STOPP in Older Patients (RASP) List and a Pharmacist-Led Medication Review in Very Old Inpatients: Impact on Quality of Prescribing and Clinical Outcome. *Drugs Aging* 2017, 34, 123–133. [CrossRef] [PubMed]

37. Frier, B.M. Hypoglycaemia in Diabetes Mellitus: Epidemiology and Clinical Implications. *Nat. Rev. Endocrinol.* 2014, 10, 711–722. [CrossRef]